What is the official website of MSDsalute ?

The official website of MSDsalute is http://www.msdsalute.it/.

What is MSDsalute's cybersecurity risk score?

MSDsalute has an AI-generated cybersecurity risk score of 749 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has MSDsalute experienced?

According to Rankiteo, MSDsalute currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSDsalute been affected by any supply chain cyber incidents ?

According to Rankiteo, MSDsalute has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSDsalute have SOC 2 Type 1 certification ?

According to Rankiteo, MSDsalute is not certified under SOC 2 Type 1.

Does MSDsalute have SOC 2 Type 2 certification ?

According to Rankiteo, MSDsalute does not hold a SOC 2 Type 2 certification.

Does MSDsalute comply with GDPR ?

According to Rankiteo, MSDsalute is not listed as GDPR compliant.

Does MSDsalute have PCI DSS certification ?

According to Rankiteo, MSDsalute does not currently maintain PCI DSS compliance.

Does MSDsalute comply with HIPAA ?

According to Rankiteo, MSDsalute is not compliant with HIPAA regulations.

Does MSDsalute have ISO 27001 certification ?

According to Rankiteo,MSDsalute is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSDsalute operate in ?

MSDsalute operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSDsalute have ?

MSDsalute employs approximately 1 people worldwide.

Does MSDsalute own any subsidiaries ?

MSDsalute presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSDsalute have ?

MSDsalute's official LinkedIn profile has approximately 11,880 followers.

What is the NAICS classification code for MSDsalute ?

MSDsalute is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does MSDsalute have a Crunchbase profile ?

No, MSDsalute does not have a profile on Crunchbase.

Does MSDsalute have a LinkedIn profile ?

Yes, MSDsalute maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msd-salute-1.

How many cybersecurity incidents has MSDsalute experienced ?

As of August 2, 2026, Rankiteo reports that MSDsalute has experienced 1 cybersecurity incidents.

How many peer or competitor companies does MSDsalute have ?

MSDsalute has an estimated 5,720 peer or competitor companies worldwide.

What types of cybersecurity incidents has MSDsalute faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSDsalute

Boost Score +25 with badge (5 left)

749

/1000

Moderate

774

/1000

Fair

MSDsalute Vendor Cyber Rating & Cyber Score

msdsalute.it

Add Your Compliance Badge

Account LinkedIn di MSD Italia.

MSDsalute A.I CyberSecurity Scoring

Scoring History

MSDsalute

MSDsalute CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

MSDsalute

Breach

9/2025

MSD060270611182...

Loading…

A.I.

MSDsalute Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSDsalute

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSDsalute in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSDsalute in 2026.

Incident Types MSDsalute vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSDsalute in 2026.

Incident History - MSDsalute (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSDsalute Subsidiaries

MSDsalute

Pharmaceutical Manufacturing

Website: http://www.msdsalute.it/

Company Size: 1

MSDPharmaceutical Manufacturing

MSD Animal HealthPharmaceutical Manufacturing

MSD LATAMPharmaceutical Manufacturing

MSD Saúde AnimalVeterinary Services

MSD Animal Health UK LtdPharmaceutical Manufacturing

MSD JordanPharmaceutical Manufacturing

MSD ÖsterreichPharmaceutical Manufacturing

MSD DanmarkPharmaceutical Manufacturing

MSD RomaniaPharmaceutical Manufacturing

MSD SverigePharmaceutical Manufacturing

MSD LebanonPharmaceutical Manufacturing

MSD NorgePharmaceutical Manufacturing

MSD FinlandPharmaceutical Manufacturing

MSD SRBIJAPharmaceutical Manufacturing

MSD EspañaPharmaceutical Manufacturing

MSD SlovenskoPharmaceutical Manufacturing

MSD Czech RepublicPharmaceutical Manufacturing

MSD MagyarországPharmaceutical Manufacturing

MSD FrancePharmaceutical Manufacturing

MSD UkrainePharmaceutical Manufacturing

MSD EgyptPharmaceutical Manufacturing

MSD Australia & New ZealandPharmaceutical Manufacturing

MSD NetherlandsPharmaceutical Manufacturing

MSD AcademyHospitals and Health Care

MSD Manufacturing Division (MMD) HaarlemPharmaceutical Manufacturing

Curare MagazineHospitals and Health Care

MSD & diabetesHospitals and Health Care

MSD SwitzerlandPharmaceutical Manufacturing

MSD TürkiyePharmaceutical Manufacturing

MSD South AfricaPharmaceutical Manufacturing

MSD BelgiumPharmaceutical Manufacturing

MSD GreecePharmaceutical Manufacturing

MSD PolskaPharmaceutical Manufacturing

MSD GCCPharmaceutical Manufacturing

MSD Animal Health Technology LabsTechnology, Information and Internet

MSD DeutschlandPharmaceutical Manufacturing

MSD PortugalPharmaceutical Manufacturing

MSD in the UKPharmaceutical Manufacturing

MSD ItaliaPharmaceutical Manufacturing

Loading…

MSDsalute Similar Companies

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Loading…

NEWS

MSDsalute CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-18556

SUMMARY

Authentication bypass using an alternate path or channel vulnerability in N-able N-central allows Authentication Bypass. This issue affects N-central: through 2026.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://uptime.n-able.com/

CVE-2026-55735

SUMMARY

Improper Verification of Cryptographic Signature in ueberauth guardian allows an unauthenticated attacker to revoke a victim's session with a forged token. Guardian.revoke/3 in lib/guardian.ex decodes the supplied token with peek/1, which performs no signature verification (it only base64-decodes the JWT header and payload). The resulting unverified claims are forwarded directly to the configured token module's revoke callback and the implementation's on_revoke callback, a state-mutating sink. The sibling operations refresh/2 and exchange/4 both call decode_and_verify first, so the signature is checked before anything acts on the claims; revoke/3 is the only state-mutating path that acts on claims without verifying the signature. An attacker who knows or guesses a victim's identifying claim values (jti, sub) can forge a JWT carrying those claims, sign it with an arbitrary key, and submit it to any endpoint that funnels a caller-supplied token into Guardian.revoke/3 (the standard logout / session-revocation pattern). When the token module mutates state keyed by the claims (whitelist deletion or blacklist insertion, for example a GuardianDb-style store), the victim's legitimate session is evicted. This is an unauthenticated session-revocation denial of service; the attacker never needs the signing secret. This issue affects guardian: from 1.0.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 8.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-55734

SUMMARY

Allocation of Resources Without Limits or Throttling vulnerability in ueberauth guardian (Guardian.Permissions module) allows a denial of service via BEAM atom-table exhaustion. This vulnerability is associated with program file lib/guardian/permissions.ex and program routines 'Elixir.Guardian.Permissions':encode_permissions!/1, 'Elixir.Guardian.Permissions':encode_permissions_into_claims!/2, 'Elixir.Guardian.Permissions':do_encode_permissions!/2. The Guardian.Permissions mixin installs a public encode_permissions!/1 function on every module that does use Guardian.Permissions. For each key of the supplied map, encode_permissions!/1 calls String.to_atom(to_string(k)) before any validation runs. The integer-value clause of do_encode_permissions!/2 then short-circuits straight to encoding without validating the key against the configured permission set, so a key with an integer value is interned as a fresh atom with no exception raised. Atoms are never garbage collected and the BEAM atom table is a fixed-size resource (default roughly 1,048,576 entries), so each unique attacker-chosen key permanently consumes one slot. An attacker who can influence a permission map that reaches encode_permissions!/1 (for example a permissions map read from a request body and passed into token issuance via encode_permissions_into_claims!/2) can mint an unbounded number of atoms and exhaust the atom table, crashing the entire BEAM node and every service running on it. The sibling decode_permissions/1 is not affected because it skips keys absent from the configured permission set. This issue affects guardian: from 2.0.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-55733

SUMMARY

Allocation of Resources Without Limits or Throttling in ueberauth guardian allows denial of service via unbounded atom creation from attacker-controlled binary input. Guardian.Permissions.AtomEncoding encodes permission scopes by passing arbitrary binaries to String.to_atom/1. When encode/3 in lib/guardian/permissions/atom_encoding.ex is called with a list, each binary entry is handled by the encode_value/3 binary clause, which calls String.to_atom(value) with no allow-list check. The perm_set argument (the application's small, finite set of legitimate permission names) is discarded, so any external string flows straight into atom creation. This encoder is selected with use Guardian.Permissions, encoding: Guardian.Permissions.AtomEncoding and reached through the imported encode/3 entry point. String.to_atom/1 creates a brand-new atom for every previously unseen binary, atoms are never garbage collected, and the BEAM atom table is fixed at roughly 1,048,576 entries by default. An application that funnels attacker-influenced permission scopes (from a request body, a JWT claim, or other external input) into encode/3 therefore mints one permanent atom per distinct value. A modest stream of varied, unauthenticated input permanently consumes the atom table and crashes the BEAM node with system_limit, taking down every application running on it. The default encoder is Guardian.Permissions.BitwiseEncoding, which is not affected. This issue affects guardian: from 2.0.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-54894

SUMMARY

Allocation of Resources Without Limits or Throttling in ueberauth guardian allows denial of service via unbounded atom creation from attacker-influenced binary input. Guardian.Plug.Keys derives connection and session namespace keys by passing arbitrary binaries to String.to_atom/1. base_key/1 in lib/guardian/plug/keys.ex converts any binary into the atom :"guardian_<input>", and the derived helpers claims_key/1, resource_key/1, and token_key/1 create a second atom on top of that. key_from_other/1 likewise converts a regex-captured binary through String.to_atom/1. The public specs advertise String.t() as a valid argument, so passing a string is documented usage, and higher-level entry points such as Guardian.Plug.current_token(conn, key: key) thread the caller-supplied key straight into these functions. String.to_atom/1 creates a brand-new atom for every previously unseen binary, atoms are never garbage collected, and the BEAM atom table is fixed at roughly 1,048,576 entries by default. An application that routes attacker-influenced data (a tenant identifier, header, or other request input) into a Guardian key therefore mints one permanent atom per distinct value. A modest stream of varied, unauthenticated input permanently consumes the atom table and crashes the BEAM node, taking down every application running on it. This issue affects guardian: from 0.1.0 before 2.4.1.

Published

Date2026-08-01

Updated

Date2026-08-01

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…